Official Title
The Efficacy and Safety of Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of Novel Coronavirus Pneumonia Patient (COVID-19) : An Observational Study
Brief Summary

There is still no effective antiviral drugs and vaccines against SARS-CoV-2 yet now. This is an obsevational study, the investigators collected the clinical information and clinical outcomes of the COVID-19 patients using anti-2019-nCoV inactivated convalescent plasma.The study is to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of COVID-19 pneumonia.

Status
Unknown status
Conditions
Coronavirus
Eligibility Criteria

Inclusion Criteria:

- The participants were diagnosed as COVID-19;

- Participants received anti-SARS-CoV-2 inactivated convalescent plasma

- Written the informed consent.

Exclusion Criteria:

- Participants lacked detailed medical history

Eligibility Gender
All
Eligibility Age
Minimum: N/A ~ Maximum: N/A
Countries
China
Locations

Shanghai Public Health Clinical Center
Shanghai, Shanghai, China

Investigator: Jun Chen
Contact: 008602137990333

Contacts

Hongzhou Lu, Ph.D
+86-021-37990333 - 3222
luhongzhou@fudan.edu.cn

Investigators

Hongzhou Lu, Ph.D, Principal Investigator
Shanghai Public Health Clinical Center

Sponsors / Collaborators
Shanghai Public Health Clinical Center
NCT Number
NCT04292340
Keywords
Plasma transfusion
Coronavirus
MeSH Terms
Coronavirus Infections